A tumor control probability model for anal squamous cell carcinoma
<p><strong>Background and purpose</strong> A recent update of the RTOG 9811, reported differing relapse rates for early and late anal squamous cell carcinoma following chemoradiotherapy (CRT). There may be a role for dose-individualization, however the dose–response relationship fo...
| Glavni autori: | , , |
|---|---|
| Format: | Journal article |
| Izdano: |
Elsevier
2015
|
| _version_ | 1826282861701890048 |
|---|---|
| author | Muirhead, R Partridge, M Hawkins, M |
| author_facet | Muirhead, R Partridge, M Hawkins, M |
| author_sort | Muirhead, R |
| collection | OXFORD |
| description | <p><strong>Background and purpose</strong> A recent update of the RTOG 9811, reported differing relapse rates for early and late anal squamous cell carcinoma following chemoradiotherapy (CRT). There may be a role for dose-individualization, however the dose–response relationship for anal cancer is not currently known.</p> Intensity-modulated radiotherapy (IMRT) has been widely adopted with multiple series published. The aim is to fit a tumor control probability (TCP) model to the published IMRT data. <p><strong>Materials and methods</strong> We performed a systematic review of PubMed and Embase databases to identify thirteen appropriate papers, including 625 patients. Predefined data fields were collected. A standard linear quadratic TCP model, which included repopulation, was fit by least squares minimization.</p> <p><strong>Results</strong> The fitted TCP curve demonstrated a dose–response relationship with α = 0.196 Gy–1. The curve suggests: in early stage tumours, a dose reduction from 50 Gy to 45 Gy reduces 2 year local control from 98% to 95%; in late stage tumours, a dose escalation from 50 Gy to 55 Gy improves the 2 year local control rate from approximately 50% to 80%.</p> <p><strong>Conclusions</strong> The published data are broadly consistent with a linear quadratic dose–response model. Dose-individualization in anal cancer should be further investigated in the context of clinical trials.</p> |
| first_indexed | 2024-03-07T00:50:13Z |
| format | Journal article |
| id | oxford-uuid:86218ab6-bddb-4eaf-a971-b6f280ad2bc4 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:50:13Z |
| publishDate | 2015 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:86218ab6-bddb-4eaf-a971-b6f280ad2bc42022-03-26T22:02:03ZA tumor control probability model for anal squamous cell carcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:86218ab6-bddb-4eaf-a971-b6f280ad2bc4Symplectic Elements at OxfordElsevier2015Muirhead, RPartridge, MHawkins, M<p><strong>Background and purpose</strong> A recent update of the RTOG 9811, reported differing relapse rates for early and late anal squamous cell carcinoma following chemoradiotherapy (CRT). There may be a role for dose-individualization, however the dose–response relationship for anal cancer is not currently known.</p> Intensity-modulated radiotherapy (IMRT) has been widely adopted with multiple series published. The aim is to fit a tumor control probability (TCP) model to the published IMRT data. <p><strong>Materials and methods</strong> We performed a systematic review of PubMed and Embase databases to identify thirteen appropriate papers, including 625 patients. Predefined data fields were collected. A standard linear quadratic TCP model, which included repopulation, was fit by least squares minimization.</p> <p><strong>Results</strong> The fitted TCP curve demonstrated a dose–response relationship with α = 0.196 Gy–1. The curve suggests: in early stage tumours, a dose reduction from 50 Gy to 45 Gy reduces 2 year local control from 98% to 95%; in late stage tumours, a dose escalation from 50 Gy to 55 Gy improves the 2 year local control rate from approximately 50% to 80%.</p> <p><strong>Conclusions</strong> The published data are broadly consistent with a linear quadratic dose–response model. Dose-individualization in anal cancer should be further investigated in the context of clinical trials.</p> |
| spellingShingle | Muirhead, R Partridge, M Hawkins, M A tumor control probability model for anal squamous cell carcinoma |
| title | A tumor control probability model for anal squamous cell carcinoma |
| title_full | A tumor control probability model for anal squamous cell carcinoma |
| title_fullStr | A tumor control probability model for anal squamous cell carcinoma |
| title_full_unstemmed | A tumor control probability model for anal squamous cell carcinoma |
| title_short | A tumor control probability model for anal squamous cell carcinoma |
| title_sort | tumor control probability model for anal squamous cell carcinoma |
| work_keys_str_mv | AT muirheadr atumorcontrolprobabilitymodelforanalsquamouscellcarcinoma AT partridgem atumorcontrolprobabilitymodelforanalsquamouscellcarcinoma AT hawkinsm atumorcontrolprobabilitymodelforanalsquamouscellcarcinoma AT muirheadr tumorcontrolprobabilitymodelforanalsquamouscellcarcinoma AT partridgem tumorcontrolprobabilitymodelforanalsquamouscellcarcinoma AT hawkinsm tumorcontrolprobabilitymodelforanalsquamouscellcarcinoma |